N/A
Completed N=248
Comparing the Efficacy of Reverse Hybrid Therapy and Concomitant Therapy
Source: ClinicalTrials.gov NCT02646332 ↗Enrolled (actual)
248
Serious AEs
0.0%
Results posted
Nov 2020
Primary outcomePrimary: Number of Participants in Which H. Pylori Was Eradicated — 124; 121 participants
Summary
Reverse hybrid therapy achieves a higher eradication rate than concomitant therapy remains unanswered.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Number of Participants in Which H. Pylori Was Eradicated |
124; 121 | — |
Eligibility Criteria
Inclusion Criteria
- Consecutive H pylori-infected outpatients, at least 20 years of age, with endoscopically proven peptic ulcer diseases or gastritis
Exclusion Criteria
- previous H pylori-eradication therapy
- ingestion of antibiotics or bismuth within the prior 4 weeks
- patients with allergic history to the medications used
- patients with previous gastric surgery
- the coexistence of serious concomitant illness (for example, decompensated liver cirrhosis, uremia)
- pregnant women
Data sourced from ClinicalTrials.gov (NCT02646332). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.